Parahuleva Mariana S, Kanse Sandip, Hölschermann Hans, Zheleva Kirila, Zandt Daniel, Worsch Michael, Parviz Behnoush, Güttler Norbert, Tillmanns Harald, Böning Andreas, Erdogan Ali
Internal Medicine I/Cardiology and Angiology, University Hospital of Giessen and Marburg, Klinikstr. 36, 35392, Giessen, Germany,
J Thromb Thrombolysis. 2014 Apr;37(3):317-25. doi: 10.1007/s11239-013-0921-0.
Factor VII Activating Protease (FSAP) activates factor VII (FVII) as well as pro-urokinase (uPA). Our goal was to evaluate the relation between plasma levels of FSAP and clinical instability in atrial fibrillation (AF) and possible effects of oral omega-3 fatty acids (FA) supplements. 101 patients with persistent AF were analyzed in the OMEGA-AF Study. Plasma FSAP levels were measured at baseline and after 12 weeks of treatment with omega-3 FA. The median FSAP antigen concentration, in contrast to FSAP activity, was higher in patients with persistent AF. The maintenance of SR after successful cardioversion (CV) did not lead to a normalization of FSAP concentration. Supplementation with omega-3 FA but not placebo significantly reduced elevated FSAP concentration. Furthermore, elevated FSAP levels did not indicate a significantly increased risk of recurrence of AF after electrical CV or cardiovascular clinical events during 1 year of follow-up. Plasma FSAP concentration was increased in patients with AF and may be involved in the pathogenesis of this condition. The possible effects of omega-3 FA on clinical AF potential could be linked with modulation of circulating FSAP levels.
凝血因子VII激活蛋白酶（FSAP）可激活凝血因子VII（FVII）以及尿激酶原（uPA）。我们的目标是评估FSAP血浆水平与心房颤动（AF）临床不稳定性之间的关系，以及口服ω-3脂肪酸（FA）补充剂的可能影响。在OMEGA-AF研究中对101例持续性AF患者进行了分析。在基线时以及用ω-3 FA治疗12周后测量血浆FSAP水平。与FSAP活性相反，持续性AF患者的FSAP抗原浓度中位数更高。成功复律（CV）后窦性心律（SR）的维持并未导致FSAP浓度正常化。补充ω-3 FA而非安慰剂可显著降低升高的FSAP浓度。此外，在1年的随访期间，FSAP水平升高并未表明电复律后AF复发或心血管临床事件的风险显著增加。AF患者的血浆FSAP浓度升高，可能参与了该疾病的发病机制。ω-3 FA对临床AF潜能的可能影响可能与循环FSAP水平的调节有关。
